SCM
LPCN icon

Squadron Capital Management’s Lipocine LPCN Stock Holding History

Squadron Capital Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.07M Buy
810,000
+360,000
+80% +$866K 0.64% 32
2026
Q1 		$3.6M Sell
450,000
-80,000
-15% -$697K 1.32% 22
2025
Q4 		$4.26M Buy
+530,000
New +$1.78M 1.8% 18

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $606M AUM

Squadron Capital Management's LPCN Position: Q2 2026 in Review

Squadron Capital Management increased its Lipocine (LPCN) stake by 80% in Q2 2026, buying an estimated $866K and bringing the position to 810,000 shares worth $2.07M. The position accounts for 0.64% of the portfolio, ranked #32.

Squadron Capital Management first reported a position in LPCN in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.26M in Q4 2025. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

  • Squadron Capital Management held 810,000 shares of Lipocine worth $2.07M as of Q2 2026.
  • Squadron Capital Management bought 360,000 Lipocine shares in Q2 2026, an estimated $866K.
  • Lipocine made up 0.64% of Squadron Capital Management's portfolio in Q2 2026, its #32 holding.
  • Squadron Capital Management first reported a position in Lipocine in Q4 2025 and has held it in 3 quarters since.
  • Squadron Capital Management's Lipocine position peaked at $4.26M in Q4 2025.
  • 36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.